Finch Therapeutics Group, Inc.
FNCHQOTCHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|
| Revenue | $107,000 | $861,000 | $18.5M | $7.7M |
| Operating income | −$83.9M | −$115.6M | −$60.0M | −$39.4M |
| Net income | −$74.8M | −$114.6M | −$58.2M | −$39.3M |
| Total assets | $55.4M | $162.9M | $225.4M | $165.3M |
| Total liabilities | $32.5M | $67.2M | $23.1M | $28.0M |
| Equity | $22.9M | $95.7M | $202.2M | −$95.7M |
| EPS (diluted) | $-46.59 | $-72.12 | $-1.48 | — |
| Shares out. | 48.1M | 47.5M | 47.5M | 8.4M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- −78374.8%
- Net margin
- −69863.6%
- Return on equity
- −326.6%
- Return on assets
- −135.0%
- Return on capital (ROCE)
- −163.5%
- Liabilities / assets
- 58.7%
- Debt / equity
- 1.42×
- Book value / share
- $0.48
- Revenue growth (YoY)
- −87.6%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Altman Z″ (distress)
- -27.49distress
- Accruals / assets
- −78.1%clean
- Piotroski F-Score
- 2/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 4 warning● 1 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 658 | 1.0 | +67.4% |
| Apr 30, 2026 | 393 | 1.0 | +32.8% |
| Apr 15, 2026 | 296 | 1.0 | +179.3% |
| Mar 31, 2026 | 106 | 1.0 | +178.9% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Delisting / listing-standard notice · Regulation FD disclosureOct 21, 2024
- Other material eventAug 12, 2024
- Delisting / listing-standard noticeMay 24, 2024
- Delisting / listing-standard noticeMay 17, 2024
- Delisting / listing-standard noticeApr 3, 2024
- Delisting / listing-standard notice · Other material eventFeb 23, 2024
- Delisting / listing-standard noticeNov 17, 2023
- Terminated a material agreementJul 7, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.